Fidelity D & D Bancorp Inc. Acquires 87 Shares of Amgen Inc. (NASDAQ:AMGN)

Fidelity D & D Bancorp Inc. increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 9.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 977 shares of the medical research company’s stock after purchasing an additional 87 shares during the period. Fidelity D & D Bancorp Inc.’s holdings in Amgen were worth $315,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Keynote Financial Services LLC increased its position in shares of Amgen by 0.6% during the second quarter. Keynote Financial Services LLC now owns 4,898 shares of the medical research company’s stock worth $1,530,000 after acquiring an additional 30 shares in the last quarter. Ascent Group LLC lifted its holdings in shares of Amgen by 0.3% in the second quarter. Ascent Group LLC now owns 10,949 shares of the medical research company’s stock valued at $3,421,000 after purchasing an additional 31 shares in the last quarter. Hofer & Associates. Inc lifted its holdings in shares of Amgen by 0.5% in the second quarter. Hofer & Associates. Inc now owns 6,477 shares of the medical research company’s stock valued at $2,024,000 after purchasing an additional 32 shares in the last quarter. Cadinha & Co. LLC boosted its position in shares of Amgen by 0.6% during the third quarter. Cadinha & Co. LLC now owns 5,209 shares of the medical research company’s stock worth $1,678,000 after buying an additional 32 shares during the period. Finally, Lansing Street Advisors grew its holdings in shares of Amgen by 1.3% during the third quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company’s stock worth $832,000 after buying an additional 32 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on AMGN shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $405.00 price target on shares of Amgen in a research report on Tuesday, October 22nd. Bank of America restated an “underperform” rating and set a $256.00 target price on shares of Amgen in a report on Tuesday. Royal Bank of Canada lowered their price target on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Citigroup reduced their price objective on shares of Amgen from $335.00 to $310.00 in a research note on Wednesday, November 27th. Finally, TD Cowen upped their target price on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $319.68.

Amgen Stock Performance

AMGN traded down $1.66 during trading on Friday, hitting $272.40. The stock had a trading volume of 98,604 shares, compared to its average volume of 2,609,521. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The firm has a market cap of $146.42 billion, a price-to-earnings ratio of 35.09, a P/E/G ratio of 2.91 and a beta of 0.55. The company has a 50 day moving average price of $303.00 and a 200-day moving average price of $314.87. Amgen Inc. has a one year low of $257.80 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the prior year, the company posted $4.96 earnings per share. Amgen’s revenue was up 23.2% compared to the same quarter last year. As a group, research analysts predict that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.49%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.